The Interactive Effect of GHR-Exon 3 and -202 A/C IGFBP3 Polymorphisms on rhGH Responsiveness and Treatment Outcomes in Patients with Turner Syndrome

Imagem de Miniatura
Arquivos
art_BRAZ_The_Interactive_Effect_of_GHR_Exon_3_and_2012_eng.pdf (386.5 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ENDOCRINE SOC
Autores
ANTONINI, Sonir R. R.
RAMOS, Ester S.
Citação
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.97, n.4, p.E671-E677, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Context: There is great interindividual variability in the response to recombinant human (rh) GH therapy in patients with Turner syndrome (TS). Ascertaining genetic factors can improve the accuracy of growth response predictions. Objective: The objective of the study was to assess the individual and combined influence of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on the short-and long-term outcomes of rhGH therapy in patients with TS. Design and Patients: GHR-exon 3 and -202 A/C IGFBP3 genotyping (rs2854744) was correlated with height data of 112 patients with TS who remained prepubertal during the first year of rhGH therapy and 65 patients who reached adult height after 5 +/- 2.5 yr of rhGH treatment. Main Outcome Measures: First-year growth velocity and adult height were measured. Results: Patients carrying at least one GHR-d3 or -202 A-IGFBP3 allele presented higher mean first-year growth velocity and achieved taller adult heights than those homozygous for GHR-fl or -202 C-IGFBP3 alleles, respectively. The combined analysis of GHR-exon 3 and -202 A/C IGFBP3 genotypes showed a clear nonadditive epistatic influence on adult height of patients with TS treated with rhGH (GHR-exon 3 alone, R-2 = 0.27; -202 A/C IGFBP3, R-2 = 0.24; the combined genotypes, R-2 = 0.37 at multiple linear regression). Together with clinical factors, these genotypes accounted for 61% of the variability in adult height of patients with TS after rhGH therapy. Conclusion: Homozygosity for the GHR-exon3 full-length allele and/or the -202C-IGFBP3 allele are associated with less favorable short-and long-term growth outcomes after rhGH treatment in patients with TS.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/402
Referências
  1. Alvarez-Nava F, 2010, J PEDIATR ENDOCR MET, V23, P773, DOI 10.1515/jpem.2010.127
  2. Audi L, 2006, J CLIN ENDOCR METAB, V91, P5038, DOI 10.1210/jc.2006-0828
  3. Bannink EMN, 2006, CLIN ENDOCRINOL, V65, P310, DOI 10.1111/j.1365-2265.2006.02594.x
  4. Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967
  5. Binder G, 2006, J CLIN ENDOCR METAB, V91, P659, DOI 10.1210/jc.2005-1581
  6. Binder G, 2008, CLIN ENDOCRINOL, V68, P567, DOI 10.1111/j.1365-2265.2007.03090.x
  7. Bondy CA, 2007, J CLIN ENDOCR METAB, V92, P10, DOI 10.1210/jc.2006-1374
  8. Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695
  9. Costalonga EF, 2011, PHARMACOGENOMIC 0405, DOI [10.1038/tpj.2011.13, DOI 10.1038/TPJ.2011.13]
  10. Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
  11. Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274
  12. Dos Santos C, 2004, NAT GENET, V36, P720, DOI 10.1038/ng1379
  13. Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
  14. Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
  15. Jogie-Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008-0028
  16. Jorge AAL, 2009, HORM RES, V71, P55, DOI 10.1159/000192438
  17. Ko JM, 2010, CLIN ENDOCRINOL, V72, P196, DOI 10.1111/j.1365-2265.2009.03681.x
  18. Kuczmarski R J, 2000, Adv Data, P1
  19. Meyer S, 2009, PHARMACOGENOMICS, V10, P1599, DOI [10.2217/pgs.09.91, 10.2217/PGS.09.91]
  20. Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019
  21. Mullis PE, 2011, BEST PRACT RES CL EN, V25, P25, DOI 10.1016/j.beem.2010.06.006
  22. Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200
  23. Pyle S. I., 1959, RADIOGRAPHIC ATLAS S
  24. Ranke MB, 2007, PEDIATR RES, V61, P105, DOI 10.1203/01.pdr.0000250039.42000.c9
  25. Ross JL, 2011, NEW ENGL J MED, V364, P1230, DOI 10.1056/NEJMoa1005669
  26. Stephure DK, 2005, J CLIN ENDOCR METAB, V90, P3360, DOI 10.1210/jc.2004-2187
  27. TANNER JM, 1966, ARCH DIS CHILD, V41, P454
  28. van der Kaay DCM, 2009, GROWTH HORM IGF RES, V19, P198, DOI 10.1016/j.ghir.2008.08.010
  29. van Pareren YK, 2003, J CLIN ENDOCR METAB, V88, P1119, DOI 10.1210/jc.2002-021171
  30. Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/42